新闻资讯

公司新闻

2024-10-25

领挚科技完成数千万元A轮融资,加速TFT生命科学产品交付及全球拓展。

2025-07-03

领挚科技生命科学全系列产品发布 | DNA微阵列合成仪及产物服务已接受订购

2025-03-20

Nature!正刊!!TFT助力钙钛矿LED登顶

2025-02-14

领挚科技完成数千万元A轮融资,加速TFT生命科学产品交付及全球拓展

2025-01-02

LinkZill大事记|2024的故事,「挚」地有声

2024-12-31

喜报|领挚科技荣获“省级研发中心”等多项荣誉

2024-12-12

新品首发 | 挚睿TruArray™高通量DNA微阵列上线!拥抱涌现!

2024-11-07

领挚科技光电产品全线亮相 | 三大重磅新品发布

2024-06-19

助力连发两篇Nature!领挚科技上半年光电业绩破新高!

2024-07-31

领挚科技超多技术岗位招募中!用半导体技术引领生命科学生产力变革!

2024-06-18

正式获评 | 领挚科技入选浙江省“专精特新”中小企业、杭州市企业高新技术研究开发中心

2024-06-18

喜报 | 领挚科技荣登2024年VBEF「医疗健康产业创新力产品榜」

2024-04-28

最强朋友圈!国内外院士学者齐聚领挚科技

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.